Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the company, MarketBeat.com reports.

Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings and welcome to the PureTech Health ...

Royalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. The company said in a filing with the US financial regulator that it plans ...

PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 - CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Alerus (ALRS) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.32 per share a year ago. These figures ...

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated ...

The portfolio managers’ pursuit of unique business models often leads them to companies defying traditional sector categorization, such as DoorDash, Affirm Holdings, and Royalty Pharma PLC.

Last month Royalty Pharma set Wall Street on fire with its oversubscribed $2.2 billion IPO, selling 77 million shares. The IPO raised around $300 million more than expected and shares surged after ...

Alerus (ALRS) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.32 per share a year ago. These figures are ...